Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded at Zacks Research

Zacks Research upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a hold rating to a strong-buy rating in a report published on Tuesday morning,Zacks.com reports.

A number of other brokerages have also recently weighed in on BAYRY. Barclays upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Finally, Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Three analysts have rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Trading Up 1.8%

Shares of Bayer Aktiengesellschaft stock opened at $12.91 on Tuesday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.71 and a current ratio of 1.14. The company has a fifty day moving average of $10.36 and a 200 day moving average of $8.83. The company has a market capitalization of $49.83 billion, a P/E ratio of -143.43, a P/E/G ratio of 4.80 and a beta of 0.66. Bayer Aktiengesellschaft has a fifty-two week low of $5.30 and a fifty-two week high of $13.00.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.